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ABSTRACT  33 
Type 2 diabetes (T2D) has been linked with increased intestinal permeability, but the clinical 34 
significance of this phenomenon is unknown.  The objective of this study was to investigate the potential 35 
link between glucose control, intestinal permeability, diet and intestinal microbiota in patients with 36 
T2D. Thirty-two males with well-controlled T2D and 30 age-matched male controls without diabetes 37 
were enrolled in a case-control study. Metabolic parameters, inflammatory markers, endotoxaemia and 38 
intestinal microbiota in individuals subdivided into high (HP) and normal (LP) colonic permeability 39 
groups, were the main outcomes. In T2D, the HP group had significantly higher fasting glucose (P = 40 
0.034) and plasma non-esterified fatty acid levels (P = 0.05) compared with the LP group. Increased 41 
colonic permeability was also linked with altered abundances of selected microbial taxa. The microbiota 42 
of both T2D and control HP groups was enriched with Enterobacteriales. In conclusion, high intestinal 43 
permeability was associated with poorer fasting glucose control in T2D patients and changes in some 44 
microbial taxa in both T2D patients and non-diabetic controls. Therefore, enrichment in the gram-45 
negative order Enterobacteriales may characterise impaired colonic permeability prior 46 
to/independently from a disruption in glucose tolerance. 47 
  48 
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New & Noteworthy 49 
 We compared metabolic and inflammatory markers, endotoxaemia and intestinal microbiota in 50 
individuals with high and normal intestinal permeability. Impaired permeability was linked to 51 
increased abundance of Enterobacteriales and impaired fasting glycaemia. However, anti-52 
hyperglycaemic medication may have confounded the results in diabetes patients.   53 
 Whilst increased intestinal permeability was associated with altered intestinal microbial 54 
composition, it was only associated with limited differences in metabolic parameters.  55 
 56 
ABBREVIATIONS 57 
Bp: base pair 58 
DPP4: dipeptidyl peptidase-4 59 
HP: high permeability 60 
hsCRP: high-sensitive C-reactive protein 61 
LP: low permeability 62 
LPS: lipopolysaccharide 63 
LBP: lipopolysaccharide binding protein 64 
NW: normal weight 65 
OTU: operational taxonomic unit  66 
OW: overweight 67 
sCD14: soluble cluster of differentiation 14 68 
TGs: triglycerides 69 
TLR-4: toll-like receptor-4 70 
51Cr-EDTA: 51Chromium-ethylendiaminretraacetate 71 
  72 
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INTRODUCTION 73 
Impaired barrier function has been hypothesised to lead to the increased uptake of antigens of both 74 
dietary and bacterial origin from the intestinal lumen into the circulation, activating the innate immune 75 
system (8). Animal studies suggest that gut microbiota composition and diet may be key factors. 76 
Increased fat content of the diet is associated with dysbiosis and increased circulating LPS, called 77 
metabolic endotoxaemia and this has been associated with changes in the gut barrier function in mice 78 
(7, 9, 22). Increased circulating LPS and bacteria have been reported (1, 12, 42), in addition to well 79 
established dysbiosis in T2D patients (26, 27, 29, 37, 40, 41, 50, 51).  The Gram-negative bacterial cell 80 
membrane component, lipopolysaccharide (LPS), is a potent ligand of the TLR-4 receptor.  TLR-4 81 
activation leads to increased levels of pro-inflammatory cytokines, such as TNF-α and interleukins, and 82 
this systemic low-grade inflammation is associated with insulin resistance (6). Administering LPS to 83 
animals and humans increases inflammatory markers and insulin resistance, corroborating a role for 84 
LPS in metabolic diseases characterised by low-grade inflammation (2, 3, 6). 85 
Impaired intestinal barrier function is suggested to be implicated in gastrointestinal and metabolic 86 
diseases, such as coeliac disease, non-alcoholic fatty liver disease and type 2 diabetes (T2D) (11, 24, 87 
33). In a recent pilot study, T2D patients were found to have increased intestinal permeability (measured 88 
by urinary recovery of 51Cr-EDTA) compared to healthy age, sex and BMI-matched subjects with small 89 
intestinal permeability correlating positively with circulating inflammatory markers (19). However, 90 
there were no associations between intestinal permeability and diet, anthropometrics or markers of 91 
metabolic control. Similarly, in a larger study a derived permeability risk score was higher in T2D 92 
patients compared to healthy controls (11). However, T2D patients and healthy individuals were not 93 
matched for BMI, age or sex in this latter study (11).  94 
However, it is unclear what initiates this increased intestinal permeability. Moreover, to date, the link 95 
between intestinal permeability, oral antidiabetic drugs (e.g. metformin), biochemical indices, diet and 96 
intestinal microbiota composition have not been thoroughly investigated.  97 
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In our previous work, we established that intestinal permeability in males with T2D was significantly 98 
higher than that of age, sex and BMI matched healthy controls, however the true clinical significance 99 
of this finding remains to be established in vivo (19). There is considerable variation in intestinal 100 
permeability with a proportion of T2D patients having intestinal permeability within what would be 101 
considered the healthy range, and similarly healthy individuals living with intestinal permeability values 102 
within the pathological range. For this reason, it is too simplistic to conclude that impaired permeability 103 
can be implicated in the aetiology of T2D in all patients. In order to investigate this phenomenon, a 104 
group of  T2D patients and age matched controls without diabetes were split into impaired intestinal 105 
permeability (high, HP) and normal permeability (low, LP) groups based on the upper 95% CI cut-off 106 
of 1.58% for colonic permeability using the 51Cr-EDTA intestinal permeability test data already 107 
established in healthy insulin sensitive individuals (19). The phenotypes of the colonic HP and LP 108 
groups were then compared in order to elucidate any potential link between intestinal permeability, gut 109 
bacterial profile and systemic metabolism. 110 
 111 
112 
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 METHODS 113 
This was a case-control study designed to investigate the role of intestinal bacteria and intestinal 114 
permeability in T2D patients and age matched control subjects without diabetes. The protocol was 115 
approved by the Central London NRES Committee (REC reference no. 11/LO/1141) and the University 116 
of Surrey Ethics Committee and was conducted according to the declaration of Helsinki.  117 
Subjects 118 
Thirty-two males with T2D and 30 males without diabetes (control subjects) were recruited through 119 
primary care and volunteer databases at the University of Surrey in 2012 and 2013. T2D had previously 120 
been diagnosed by the general practitioner of the participants. Women were excluded from this initial 121 
study due to the potential effect of the menstrual cycle on outcome measures in addition to the 122 
contraindication of administration of a radioactive tracer (51Cr-EDTA) to healthy females who may be 123 
of child bearing age. All subjects provided written informed consent. Exclusion criteria included use of 124 
antibiotics in the previous three months, use of anti-inflammatory medications (except a low dose 125 
aspirin (75mg/day)), diuretics, inflammatory bowel disease, coeliac disease and irritable bowel disease. 126 
Mild dyslipidaemia and hypertension were not considered reasons for exclusion. Renal function was 127 
tested (eGFR > 60) to ensure suitability for the 51Cr-EDTA intestinal permeability test. The T2D patient 128 
group and control group were each split into HP and LP groups with a cut-off value of 1.58 % urinary 129 
51Cr-EDTA recovery (6-24 h after administration of the label). 130 
Dietary intakes 131 
Subjects were instructed to avoid probiotic food items, fermented dairy such as yogurt and cheese in 132 
addition to prebiotic supplements for two weeks before the test day, this was assessed by a 7-day diet 133 
diary. Amounts were estimated using normal household measurements. The diet diaries were analysed 134 
in DietPlan6 (Forestfield Software Ltd, Horsham, UK).  135 
Faecal sample collection 136 
Subjects collected faecal samples at home using universal sterile polystyrene containers. Faecal samples 137 
were initially stored at -20°C and subsequently at -80°C for long term storage.   138 
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Blood pressure, anthropometrics and biochemistry 139 
After having emptied their bladder, body weight and body composition was measured by bioimpedance 140 
(Tanita, Arlington Heights, IL, USA). Waist circumference was measured at the level of the naval with 141 
a tape measure. Blood pressure was measured after 5 minutes rest and the mean of three readings 142 
calculated (Omron MX3 Plus, Omron Healthcare Europe, Milton Keynes, United Kingdom). A fasting 143 
blood sample (8 mL) was collected after a 10 hour overnight fast at the CEDAR centre of the Royal 144 
Surrey County Hospital. Blood was collected into EDTA tubes, serum tubes containing clotting 145 
activator and pyrogen free tubes for measurements of HbA1c, glucose, insulin, inflammatory markers, 146 
lipids and LPS. Blood samples were centrifuged at 3000 x g at 4°C for 10 minutes and serum and plasma 147 
stored at -20°C or -80°C as appropriate.  148 
Intestinal permeability  149 
Intestinal permeability was measured by 24h urinary excretion of orally administered 51Cr-EDTA as 150 
previously described (19). The 51Cr-EDTA was administered after an overnight fast and patients were 151 
asked to collect all their urine in the next 24 hours. The urine was collected into one container for the 152 
first 6 hours and into a separate container for 6-24 hours. The first 6 hours of collection is considered 153 
to represents small intestinal permeability and the 6-24h 51Cr-EDTA recovery represents the colonic 154 
permeability. The adequacy of the urine collection was assessed using questionnaires on the 155 
completeness of the urine collection.  156 
 157 
Biochemical Analyses  158 
Whole blood glucose concentrations were measured immediately using the glucose oxidase method on 159 
the YSI 2300 STAT Plus (YSI Life Sciences, Fleet, UK) with a precision of 2% (or 0.2 mmol/L) and a 160 
linear range up to 50 mmol/L. The average intra-assay CV was 4.8% and inter-assay CV was 5.8%. 161 
Plasma insulin was analysed in duplicate using a radioimmunoassay (Millipore, Billerica, MA) with an 162 
inter-assay CV of 12.6% and average intra-assay CV of 7.7%. The sensitivity of the assay was 16.29 163 
pmol/L. Serum hsCRP and HbA1c were measured by an accreditated laboratory, the Surrey Pathology 164 
Partnership and serum IL-6 and TNF-α were measured using a Luminex platform and Biorad bio-plex 165 
8 
 
kits and software. The limit of detection were 0.03mg/l for hsCRP, 5 pg/mL for TNF-α and 0.7pg/ml 166 
for IL-6. Triglycerides (TGs), total cholesterol, HDL cholesterol, and non-esterified fatty acids (NEFA) 167 
were measured on an ILab650 using commercially available kits (Randox Laboratories, UK, and 168 
Instrumentation Laboratory, UK). Average intra-assay CVs were 1.4%, 1.9%, 0.6% and 1.0% and inter-169 
assay CVs were 1.9%, 3.0%, 1.1% and 1.8% and detection limits were 0.1 mmol/L, 0.22 mmol/L, 0.189 170 
mmol/L, 0.072 mmol/L for TGs, total cholesterol, HDL cholesterol, and NEFA, respectively. LDL 171 
cholesterol concentration was calculated using the Friedewald formula. LPS was measured in duplicate 172 
using Endosafe-MCS (Charles River Laboratories, Lyon, France) as previously described (15). Samples 173 
were diluted from 1/20 to 1/200 and the samples were validated for recovery and coefficient of variation 174 
determination. The limit of detection was 0.005 EU/ml. Serum LPS binding protein (LBP) and sCD14 175 
concentrations were measured using a solid-phase enzyme-linked immunosorbent assays (ELISA) 176 
according to the manufacturer’s instructions (Hycult Biotechnology, Uden, the Netherlands). Sera were 177 
diluted 1/10 with the appropriate buffer and homogenised by vortex before further dilution to 1/200 178 
(sCD14) and 1/1000 (LBP). Detection limits were 4.4 and 1.56 ng/mL and the average intra-assay CVs 179 
were 3.9% and 8.5% and inter-assay CVs were 19.6% and 15.5% for LBP and sCD14, respectively.   180 
DNA Extraction 181 
DNA was extracted from defrosted faecal samples using the PowerFecalTM DNA Isolation Kit (MO 182 
BIO Laboratories Inc., Carlsbad, CA, USA) according to the manufacturer’s instructions. The DNA 183 
concentration and quality were measured by NanoDrop 2000 (Thermo Scientific) and Qubit 2.0 184 
fluorometer (Invitrogen). Samples with a DNA concentration >50 ng/µL was used for sequencing. Due 185 
to unsuccessful DNA extraction for some samples, bacterial data are only available for a subset of T2D 186 
patients (n = 23) and controls (n = 27).  187 
Amplification and High-Throughput Sequencing  188 
DNA amplification and sequencing were performed as previously described (14). Briefly, the V4 and 189 
V5 region of the bacterial 16S rRNA gene was amplified from extracted DNA with universal primers 190 
(U515F: 5’-GTGYCAGCMGCCGCGGTA and U927R: 5’-CCCGYCAATTCMTTTRAGT). Forward 191 
fusion primers consisted of the GS FLX Titanium primer A and the library key (5’ -192 
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CATCTCATCCCTGCGTGTCTCCGACTCAG) together with one of a suite of sixteen 10-base 193 
multiplex identifiers (MIDs 1–16) (Roche Diagnostics Ltd, UK). Reverse fusion primers included the 194 
GS FLX Titanium primer B and the library key (5’-CCTATCCCCTGTGTGCCTTGGCAGTCTCAG). 195 
Amplification was performed with FastStart HiFi Polymerase (Roche Diagnostics Ltd, UK) using the 196 
following cycling conditions: 94°C for 3 min; 30 cycles of 94°C for 30 s, 55°C for 45 s, 72°C for 1 min; 197 
followed by 72°C for 8 min. Ampure XP magnetic beads (Beckman Coulter) were used for purification 198 
of amplicons. Amplicon concentration was assessed using the fluorescence-based Picogreen assay 199 
(Invitrogen) and concentrations normalized before pooling. Amplicon pools were immobilised and 200 
amplified on beads by emulsion PCR using Lib-L emPCR kits (Roche Diagnostics Ltd, UK). 201 
Unidirectional sequencing from the forward primer was performed on the 454 GS FLX Titanium 202 
platform according to the manufacturer’s instructions (Roche Diagnostics Ltd, UK). 203 
Quantification of bacterial groups by quantitative PCR Total bacteria and the bacterial groups 204 
Bifidobacterium, Roseburia, Lactobacillus, Enterobacteriaceae, Clostridium leptum, and Clostridium 205 
coccoides groups were quantified by quantitative PCR (qPCR) on a QuantStudio 7 Flex Real-time 206 
system (Life technologies, USA). The qPCR primers are described in Table 1. A typical 20 µl qPCR 207 
reaction contained 0.3µM of each (forward and reverse) primer, 10 µl GoTaq qPCR master mix, 7.8 µl 208 
of nuclease-free water and 5 – 20 ng of template genomic DNA extract. The qPCR cycling protocol 209 
consisted of 1x initial denaturation cycle at 95oC for 2 minutes followed by 40x denaturation at 95oC 210 
for 15 seconds, annealing at 55oC for 30 seconds and extension at 72oC for 30 seconds; fluorescence 211 
was measured after each cycle and 1x dissociation – 60 – 95oC. 212 
Quantitation of each target in the samples was determined based on a standard curve of each target 213 
using purified target DNA template. A 10-fold dilution series ranging from 1x104 to 1x108 copies of 214 
each target gene was prepared in nuclease-free water and analysed in triplicate. The test samples were 215 
analysed in 96-well plates (MicroAMP Optical plates, Life Technologies, USA), along with the 216 
standard. The qPCR software generated the standard curve (based on the average of each standard) and 217 
computed the template concentrations. The amplification of a single product by the primer sets used 218 
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was confirmed by analysis of the dissociation profile of each target and agarose gel electrophoresis of 219 
a standard PCR reaction using each primer set, the same cycling conditions and DNA template.   220 
Bioinformatics and Statistical Analysis 221 
The sequences were processed in Qiime (10) using the AmpliconNoise (39) pipeline that utilises 222 
flowgram information of the sequences to correct for errors. The samples were demultiplexed by exact 223 
matching of both barcode and primer and the sequences filtered and trimmed based on identification of 224 
low quality signals (38). The filtered flowgrams were clustered to remove platform-specific errors and 225 
converted into sequences using the PyroNoise algorithm. The sequences had barcodes and degenerate 226 
primers removed prior to trimming at 500 base pairs (bp). They were then further clustered by SeqNoise 227 
to remove PCR single base errors. In the final step, the Perseus algorithm was used to identify chimeras. 228 
The denoised sequences were classified using the standalone RDP classifier (46). From this, taxa 229 
frequencies at five different levels: Phylum, Class, Order, Family and Genus; were calculated. 230 
Additionally, a non-supervised approach was used, operational taxonomic units (OTUs) were generated 231 
at 3% divergence following pair-wise global sequence alignment and hierarchical clustering with an 232 
average linkage algorithm. To improve resolution at the OTU level, sequences were also compared with 233 
databases at the NCBI website (http://blast.ncbi.nlm.nih.gov/Blast.cgi). Further statistical analyses were 234 
performed in R using the tables and data generated as above as well as the meta-data associated with 235 
the study. For community analyses (including alpha and beta diversity analyses and permutation 236 
ANOVA using distance measures (adonis function)) we used the vegan (http://cran.r-237 
project.org/web/packages/vegan/) package. To calculate Unifrac distances (that account for 238 
phylogenetic closeness), we used the phyloseq (31), ape (34), and phangorn (43) packages. To 239 
determine significant differences in bacterial abundances between the groups, we used 240 
DESeqDataSetFromMatrix() function from DESeq package with a significance value cut-off of 0.05. 241 
This function allows negative binomial GLM fitting (as abundance data from metagenomic sequencing 242 
is overdispersed) and Wald statistics for abundance data and identifies species with log-fold changes 243 
between different conditions. General scripts and tutorials for the above analyses are available at 244 
http://userweb.eng.gla.ac.uk/umer.ijaz#bioinformatics. 245 
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Data are presented as mean and SD or median and interquartile range as appropriate. T2D, OW and NW 246 
groups were compared using a one-way ANOVA with Sidak corrections for multiple comparisons using 247 
OW controls as the control group. Non-parametric data was tested using the Kruskal-Wallis test with 248 
Dunn’s post-hoc tests. Pair-wise comparisons of HP and LP groups were performed using unpaired t-249 
tests for parametric data and Mann-Whitney tests for non-parametric data. RT qPCR total bacteria 250 
values are presented as log10 of values. Values for bacterial groups were normalised to total bacteria. 251 
Where appropriate, p-values were adjusted for multiple corrections using the Benjamini-Hochberg 252 
method (5). Data were analysed in GraphPad Prism 6, SPSS 22 and R. The level of significance was 253 
set at P < 0.05.  254 
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RESULTS 255 
In an exploratory analysis the 30 non-diabetic controls were split into two groups: normal weight (NW) 256 
controls (n=14) matched on age and overweight/obese (OW) controls (n=16) matched to the diabetes 257 
patients on age and BMI. The anthropometric, dietary and clinical data for T2D, OW controls, and NW 258 
controls are shown in Table 2.  259 
Six of the T2D patients were diet/exercise controlled; the remaining 26 patients were on various oral 260 
anti-diabetic medications (n): Metformin (12), sulfonylureas (1), DPP4 inhibitor (1), metformin and 261 
DPP4 inhibitor (4), metformin and sulfonylureas (5), sulfonylureas and DPP4 inhibitor (1), metformin, 262 
sulfonylureas and DPP4 inhibitor (1), and metformin, DPP4 inhibitor and thiazolidinedione (1). All 263 
patients had been on a stable treatment for at least three months prior to taking part in the study.  Other 264 
medications taken by T2D patients included low lipid lowering medications (mainly statins) (21), blood 265 
pressure lowering medications (16), omeprazole (3), levothyroxine (2), fenofibrates (2), Betahistine 266 
hydrochloride (1) and medications for incontinence (2), benign prostate hyperplasia (3), fungal infection 267 
(2), hay fever (2), asthma (inhaler) (1), and depression (1). 268 
One NW and one OW control subject were taking statins and two OW controls were taking blood 269 
pressure medication. Other medications used in the control groups were asthma inhalers (4), benign 270 
prostate hyperplasia medication (1), antidepressant (1), mysoline (1), epilim (1), becotide (1), beconase 271 
(1), qvar (1) and dutasteride (1). 272 
Biochemical Outcomes  273 
Fasting glucose was significantly higher in the T2D patients compared with OW controls. HOMA %B 274 
was significantly higher in OW controls compared with both T2D patients and NW controls (P = 0.0013 275 
and P = 0.0268, respectively), whereas fasting insulin concentrations, insulin sensitivity (HOMA %S) 276 
and insulin resistance (HOMA IR) were only significantly different between control groups (P = 0.0418, 277 
P = 0.0385 and P = 0.0383, respectively).   278 
Serum total and LDL cholesterol concentrations were lower and NEFA concentrations higher in T2D 279 
patients compared with OW controls (P < 0.0001, P < 0.0001, and P = 0.0092, respectively). HDL 280 
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cholesterol was significantly lower in OW controls than in NW controls (P = 0.0325). LBP (P = 0.0055) 281 
and hsCRP concentrations (P = 0.0163) were higher, but LPS concentrations were lower (P = 0.0432) 282 
in OW controls compared with NW controls. There were no significant differences between groups in 283 
TGs, sCD14, IL-6 and TNF-α concentrations, although IL-6 concentrations tended to be higher in the 284 
OW controls compared to NW controls (P = 0.0669).   285 
Intestinal Permeability 286 
There were no significant differences in the recovery of 51Cr-EDTA in urine between groups (Table 2).  287 
Dietary Assessment  288 
No significant differences in energy intake between groups were observed (Table 2). However, T2D 289 
patients reported significantly lower sugar intake (g/day), total fat (g/day) and saturated fat (g/day and 290 
percentage of energy) intakes than OW controls (P = 0.0252, P = 0.0139, P = 0.0013 and P = 0.0156, 291 
respectively). Fat percentage of energy was higher in the OW control group than in the NW control 292 
group (P = 0.0286). 293 
Bacterial community structure 294 
Due to unsuccessful DNA extraction (DNA concentration <50 ng/ml) for a number of samples, the 295 
qPCR data set consisted of n = 23 for the T2D group, n = 15 for the OW group and n = 12 for the NW 296 
group. After excluding samples with <500 bp, the next-generation sequencing data set consisted of 20, 297 
13 and 12 for the T2D, OW and NW group, respectively. 298 
Consistent with previous reports the predominating phyla were Bacteroidetes and Firmicutes followed 299 
by unclassified bacteria and Proteobacteria. There were no significant differences in alpha-diversity, 300 
richness or evenness indices between groups (Table 2). Ordination plots did not show any clustering of 301 
T2D patients and control groups (Figures 1a and 1b). However, comparison of bacterial abundances 302 
showed significant differences at the order, genus and OTU levels with higher abundance of 303 
Enterobacteriales, unclassified Enterobacteriaceae, and E. coli (OTU 5), respectively, in T2D patients 304 
(Figure 1c-e). No significant differences between groups were found at the phylum, class or family 305 
levels in the next-generation sequencing data set.  306 
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Real-time PCR measurements showed that Lactobacillus spp., C. leptum and C. coccoides levels were 307 
significantly higher in T2D patients compared with OW controls (Figure 2). Total bacteria was 308 
significantly higher in NW controls than in OW controls, but no other significant differences between 309 
OW and NW control groups were found. However, there was a trend for Enterobacteriaceae with lowest 310 
levels observed in NW controls and highest levels in the T2D group.  311 
Correlations between clinical outcomes 312 
Intestinal permeability did not correlation with clinical outcomes in any group (Figure 3). However, in 313 
T2D patients LPS correlated with beta-cell function (r = 0.52, adj. P = 0.0025) and fasting glucose (r = 314 
-0.36, adj. P = 0.049), whereas hsCRP correlated with LBP (r = 0.52, adj. P = 0.0019), IL-6 (r = 0.36, 315 
adj. P = 0.0416) and BMI (r = 0.48, adj. P = 0.0034) and LBP correlated with fasting glucose (r = 0.35, 316 
adj. P = 0.0488). Furthermore waist circumference and BMI correlated positively with insulin 317 
resistance, TGs, and fasting insulin and inversely with insulin sensitivity. Few significant correlations 318 
were found in the control groups.  319 
Comparison of high permeability (HP) and low (normal) permeability (LP) groups 320 
As the density of bacteria is highest in the colon we explored whether clinical parameters, dietary 321 
intakes (Tables 3 and 4) and intestinal bacterial abundances (Figure 4) differed between those with high 322 
and normal colonic permeability. Time since diagnosis of diabetes was similar in the LP and HP 323 
diabetes groups (mean: 4.6 years (range: 0.1 to 10 years) and 4.7 years (range: 0.5 to 11 years), 324 
respectively). 325 
Anthropometrics, biochemistry and diet 326 
T2D patients in the HP group had significantly higher fasting glucose and NEFA concentrations than 327 
those in the LP group. No significant differences in inflammatory markers or dietary intakes were 328 
detected between groups, although there were a trend towards a lower total carbohydrate intake and 329 
higher BMI in the HP group (Table 4). In contrast, in the controls, the HP group had significantly lower 330 
body weight, higher HDL cholesterol concentration and lower total energy and absolute sugar, protein 331 
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and dietary fibre intakes than the LP group. Inflammatory markers and other glucose tolerance markers 332 
did not differ between control LP and HP groups (Table 3). 333 
Differences in intestinal bacterial abundances  334 
No significant differences in overall bacterial community composition between LP and HP for both 335 
T2D and control groups were found (adonis analysis, P > 0.7). As for bacteria abundances, the order 336 
Selenomonadales and Prevotella (OTU 14) were higher and Enterobacteriales and an unclassified 337 
Ruminococcaceae (OTU 20) were lower in the LP group compared to the HP T2D group. In controls, 338 
Enterobacteriales and Blautia (OTU 50) were enriched in the HP group. Accessions numbers for OTUs 339 
are provided in Table 6.  340 
Enterobacteriales enrichment therefore appears to characterise high colonic permeability in both T2D 341 
patients and healthy controls (Figure 4). No significant differences at the phylum level, in diversity, 342 
richness, evenness indices (Table 5) or any of the bacterial groups measured by qPCR between HP and 343 
LP groups were found (data not shown). 344 
Retrospective analysis: effect of metformin on gut microbiota in diabetes patients 345 
Whilst this study was underway, several studies were published indicating that metformin has a 346 
profound effect on the gut microbiota composition in both animal and human studies (17, 21, 25, 32, 347 
44). Although the study was not powered to look at the effects of medications, an exploratory 348 
investigation into the effects of metformin was undertaken. Bacterial data were available for seven non-349 
metformin treated patients and 13 metformin treated patients. We found no significant effect of 350 
metformin on overall microbiota composition (P > 0.5, Figure 5a).  However, the orders 351 
Enterobacteriales and Erysipelorichales, the family Enterobacteriaceae and an unclassified 352 
Enterobactericeae at the genus level and E. coli (OTU 5) at the species-like level were significantly 353 
enriched following metformin treatment (Figure 5b-e). In contrast, the orders Selenomonadales and 354 
unclassified Clostridia, the families Peptostreptococcaceae and Clostridiaceae 1, the genus Clostridium 355 
cluster XI and three OTUs belonging to the Firmicutes in addition to Sutterella (Proteobacteria) were 356 
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decreased in metformin treated patients (Figure 5b-e). No significant differences were found in bacterial 357 
groups measured by RT PCR (data not shown) between metformin and non-metformin treated patients.  358 
There were no statistically significant differences in intestinal permeability, biochemistry variables or 359 
dietary intakes between metformin and non-metformin treated patients, although IL-6 and TNF-α 360 
tended to be higher (IL-6: 12.9 ± 1.6 vs 7.9 ± 1.3 pg/mL, p = 0.069; TNF-α: 13.0 (5.0-22.3) vs 5.0 (5.0-361 
13.0) pg/mL, P = 0.093) and total cholesterol and LDL cholesterol tended to be lower with metformin 362 
use (total cholesterol: 3.2 ±0.2 vs 3.9 ± 0.3 mmol/L, p = 0.051; LDL cholesterol: 1.8 ± 0.1 vs 2.4 ± 0.2 363 
mmol/L, P = 0.074).   364 
  365 
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DISCUSSION 366 
In this study we have measured markers of glucose tolerance, inflammation, endotoxaemia, intestinal 367 
permeability and intestinal bacterial community structure in the same individuals, investigating for the 368 
first time whether there is a potential link between intestinal permeability and glucose 369 
control/inflammation in T2D, as a first translation from the extensive and seemingly consistent animal 370 
literature. Our findings do not suggest strong links between intestinal permeability and the microbiota, 371 
inflammation and diet exist in T2D patients. Intestinal permeability did not differ significantly between 372 
NW, OW and T2D patients, although it was numerically higher in T2D patients. This is in contrast with 373 
our previous study (19), however, a relatively large proportion of the controls were found to above the 374 
95% CI cut-off for ‘normal’ total and colonic permeability established in our previous work. Previously 375 
we established “normal permeability” in those with “normal insulin sensitivity” established by HOMA 376 
(mean HOMA IR of 1.0) . However in the current study, the non-diabetic  group was recruited  to be a 377 
phenotypic match to the diabetes group and so  had with a much broader range of background insulin 378 
sensitivity, more representative of the general population.. Fat intake was significantly higher in the 379 
OW group compared with the T2D patients and a high- fat diet has been demonstrated to induce gut 380 
barrier dysfunction (7, 45). The lower sugar and fat intakes in T2D patients suggest they may have 381 
modified their diet since being diagnosed with diabetes, however very few significant correlations 382 
between dietary intakes and microbial abundances were found in the T2D group (data not shown). 383 
Comparison of the LP and HP groups revealed that high permeability was associated with lower 384 
Selenomonadales levels and Enterobacteriales enrichment of the intestinal microbiota, higher fasting 385 
glucose (as a potential indicator of impaired hepatic glucose output) and elevated serum NEFA (as a 386 
proxy for adipose tissue dysfunction) in T2D. However, in contrast to the animal literature and our 387 
recent pilot study (19), there was no association between intestinal permeability and inflammatory 388 
markers. The patients in the present study has a better glucose control than those in the pilot study based 389 
on fasting glucose, HbA1c and HOMA-IR. This could potentially have made it more difficult to detect 390 
associations between outcomes. The use of medications may also have confounded the association 391 
between inflammatory markers and intestinal permeability and partly explain the lack of a significant 392 
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difference in intestinal permeability between T2D patients and controls in the current study. A higher 393 
proportion of T2D patients (>80% vs 65%) was taking anti-hyperglycaemic medication than in the pilot 394 
study by Horton et al (19). Also, more than 50% of the participants were taking of lipid lowering and/or 395 
blood pressure lowering medications in the present study. Statins and hypotensive medications have 396 
been demonstrated to have anti-inflammatory effects (4, 47).  397 
Although BMI and body fat percentage were not significantly different between HP and LP groups, the 398 
slightly higher BMI and body fat percentage in the T2D HP group may contributed to the elevated 399 
fasting glucose and NEFA, independently from the increased intestinal permeability. With no 400 
significant difference in HbA1c, inflammatory markers or insulin sensitivity between HP and LP 401 
groups, the clinical significance of impaired intestinal barrier function remains uncertain. However, in 402 
the healthy matched controls, increased intestinal permeability was again associated with elevated 403 
Enterobacteriales levels.  404 
 405 
We observed a common feature, higher abundance of the gram-negative bacteria Enterobacteriales in 406 
both HP T2D and control subgroups, suggesting Enterobacteriales enrichment may be mechanistically 407 
linked to increased colonic permeability irrespective of glucose tolerance status. Although Gram-408 
negative bacteria have been suggested to influence gut barrier function by elevating LPS levels in the 409 
gut lumen (6), recent studies suggests some Gram-negative bacteria (e.g. Akkermansia muciniphila) 410 
may beneficial to the host (13, 36). Nonetheless, Proteobacteria and E. coli enrichment has also been 411 
observed in patients with inflammatory bowel disease which is associated with increased intestinal 412 
permeability. The role of Proteobacteria and E. coli in disease pathogenesis remains uncertain (20, 23, 413 
30). However, Enterobacteriaceae enrichment has been observed in other clinical scenarios, such as 414 
following gastric bypass surgery (RYGB), with no detrimental effects to the host. In the case of RYGB 415 
it even concurs with resolution of T2D (18).  416 
T2D patients with high colonic permeability had lower abundances of Selenomonadales and Prevotella. 417 
The lower abundance of Prevotella may be related to the lower carbohydrate intake in the HP group. 418 
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Prevotella is generally thought to be beneficial to the host (48), although the Prevotella species, P. 419 
copri, has been linked to insulin resistance and glucose intolerance (35). The role of Selenomonadales 420 
in human health is unclear, but it contains short-chain fatty acid (SCFA) producing bacteria which may 421 
be beneficial in terms of gut health (28).  422 
The overall higher abundance of Enterobacteriales, unclassified Enterobacteriaceae and E. coli in T2D 423 
patients compared to matched-controls, may partly be due to the use of oral anti-diabetic medication 424 
(17). We confirmed this in a retrospective subgroup analysis comparing metformin with non-metformin 425 
treated patients showing that these bacterial taxa were indeed enriched in metformin treated patients 426 
confirming findings from clinical trials (32, 49) and other cross-sectional studies (17, 21). Thus, 427 
enrichment of Enterobacteria in the T2D group compared with healthy controls (Figure S2) may be 428 
attributed to metformin treatment and may not be a characteristic of the intestinal microbiome of T2D 429 
patients per se. This emphasises the importance of taking medications into account when comparing 430 
populations with a health condition, with healthy controls. However, this remains an issue with 431 
translating into human T2D due to the almost ubiquitous use of anti-diabetic medication in patients. 432 
Importantly, it must be noted that in the present study the control group showed the same relationship 433 
between Enterobacteriales and intestinal permeability, without any confounding effects of medication. 434 
Also, a similar proportion of the T2D patients used metformin in the LP and HP groups. This indicates 435 
that factors other than metformin use may have resulted in the further increase in Enterobacteriales 436 
abundance in the HP T2D group.   437 
 A higher abundance of Blautia in the control HP group was surprising. The exact composition of this 438 
taxa may be crucial as individuals with normal glucose tolerance and T2D patients have been reported 439 
to display enrichment with different members of Blautia (51). Interestingly metformin use reduced the 440 
abundance of a number of bacteria, including Blautia, in high-fat diet fed mice and this was associated 441 
with improved glucose control (44). 442 
No difference in species richness between control and diabetes patients and between HP and LP groups 443 
(Table 5) were found in this study which is in contrast to previous findings (17, 27). Again, metformin 444 
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may also have played a role by modifying the intestinal microbiota in a favourable manner. In the study 445 
by Forslund et al. (17) in those patients taking metformin the gene richness median and distribution 446 
resembled those of the non-diabetic controls when compared to the non-metformin treated diabetes 447 
patients. However, the small sample size of the present study is a limitation and may explain the lack 448 
of significant differences between groups.  449 
Further limitations to this study are primarily the hypothesis generating nature of the work and the fact 450 
only men were included in the study. However, in contrast to animal models of T2D, medication use is 451 
ubiquitous in patients with T2D, especially in the UK with respect to the prescription of statins and 452 
metformin. Understanding the implication of oral medication and the interaction between different 453 
drugs, the interactions with diet and the disease process on the microbiome is likely to be important 454 
when conducting future large scale clinical trials. 455 
In conclusion, impaired colonic permeability was associated with a modest elevation in fasting glucose 456 
and NEFA in T2D patients. Both in non-diabetic controls and T2D, high permeability was characterised 457 
by a higher abundance of Enterobacteriales, however there was no indication from the measurements 458 
conducted in this study that this increased the risk of metabolic disease in the control group. Metformin 459 
is a clear confounding factor when comparing T2D patients with healthy controls; however, despite the 460 
increase in Enterobacteria with metformin treatment, this did not have a detrimental effect on the 461 
metabolic phenotype.  462 
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Table 1. Primers used for qPCR 666 
Target Primer 
Name 
Sequence Product 
bp 
Clostridium leptum 
subgroup  
C-leptF  GCACAAGCAGTGGAGT  239 
 C-leptR  CTTCCTCCGTTTTGTCA  
Clostridium coccoides 
subgroup 
C-cocF  AAATGACGGTACCTGACTAA  440 
 C-cocR  CTTTGAGTTTCATTCTTGCGAA  
Roseburia RosF  TACTGCATTGGAAACTGTCG  230 
 RosR  CGGCACCGAAGAGCAAT  
Lactobacillus group  LacF  AGCAGTAGGGAATCTTCCA  341 
 LacR  CACCGCTACACATGGAG  
Bifidobacterium  BifF  GCGTGCTTAACACATGCAAGTC  126 
 BifR  CACCCGTTTCCAGGAGCTATT  
All bacteria UnivF  TCCTACGGGAGGCAGCAGT  466 
 UnivR  GACTACCAGGGTATCTAATCCTGTT  
Enterobacteriaceae EcoF CATTGACGTTACCCGCAGAAGAAGC 190 
 EcoR CTCTACGAGACTCAAGCTTGC  
 667 
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Table 2. Anthropometric characteristics, clinical parameters and dietary intakes in T2D patients, 669 
overweight (OW) and normal weight (NW) controls. Data are presented as means (SD) or medians 670 
(interquartile range). 671 
 T2D Control OW Control NW P-value 
n 32 16 14 -  
Age (years) 57.9 (6.2) 57.3 (7.2) 56.6 (7.4) ns 
Body weight (kg) 88.4 (12.8) 91.2 (8.0) 68.3 (6.1)a <0.0001 
BMI (kg/m2) 28.4 (25.8-30.8) 28.3 (26.7-29.8) 22.5 (20.4-23.6)a <0.0001 
Body fat (%) 25.9 (4.9) 26.2 (4.6) 17.6 (5.0)a <0.0001 
Waist circumference (cm)b 102.1 (10.4) 103.3 (9.4) 84.7 (6.3)a <0.0001 
Fasting glucose (mmol/L) 6.0 (5.3-7.2)a 4.7 (4.4-5.0) 4.4 (4.2-4.9) <0.0001 
Fasting insulin (pmol/L) 80.1 (49.3-110.0) 59.9 (47.1-107.8) 41.6 (35.0-52.0)a 0.0032 
HOMA2 %B 102.0 (43.6)a 151.5 (59.3) 109.8 (22.3)a 0.0023 
HOMA2 %S 55.8 (41.8-84.4) 81.6 (42.7-102.7) 116.3 (91.5-141.8)a 0.0012 
HOMA2 IR 1.8 (1.2-2.4) 1.2 (1.0-2.4) 0.9 (0.7-1.1)a 0.0011 
HbA1c (mmol/mol) 49.0 (9.47) n/a n/a -  
HbA1c (%) 6.6 (0.9) n/a n/a -  
BP sys (mm Hg)b 135 (11) 133 (12) 118 (8)a <0.0001 
BP dia (mm Hg)b 84 (7) 86 (7) 78 (8)a 0.0052 
Total Cholesterol (mmol/L) 3.4 (0.9)a 5.1 (1.0) 5.1 (0.9) <0.0001 
HDL Cholesterol (mmol/L) 1.0 (0.3) 1.1 (0.3) 1.4 (0.4)a 0.0009 
LDL Cholesterol (mmol/L) 2.0 (0.8)a 3.5 (0.8) 3.3 (0.7) <0.0001 
NEFA (mmol/L) 0.67 (0.25)a 0.45 (0.215) 0.47 (0.25) 0.0047 
TAGs (mmol/L) 1.00 (0.40) 1.03 (0.45) 0.93 (0.22) ns 
51Cr-EDTA 0-6h (%) 1.6 (0.9) 1.4 (0.7) 1.5 (0.6) ns 
51Cr-EDTA 6-24h (%) 1.4 (1.1-2.1) 1.3 (0.9-1.6) 1.6 (1.3-1.9) ns 
51Cr-EDTA total (%) 3.4 (1.6) 2.7 (1.0) 3.0 (0.9) ns 
LPS (EU/mL)b 0.63 (0.48-1.15) 0.49 (0.37-0.85) 0.84 (0.73-1.21)a ns 
LBP (μg/mL) 10.8 (8.7-13.0) 12.1 (10.7-13.4) 9.0 (7.4-10.2)a 0.0112 
sCD14 (μg/mL) 1.0 (0.8-1.2) 1.0 (0.8-1.3) 0.9 (0.8-1.1) ns 
hsCRP (mg/L) 1.36 (0.55-2.06) 1.32 (0.81-3.35) 0.44 (0.26-1.23)a 0.0194 
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IL-6 (pg/mL) 11.6 (7.0-13.9) 19.6 (7.4-36.0) 7.0 (5.5-18.4) ns 
TNF-α (pg/mL) 13.0 (5.0-22.3) 7.0 (5.0-28.9) 6.0 (5.0-7.3) ns 
Shannon indexc 3.294 (2.981-
3.580) 
3.186 (3.139-
3.387) 
3.348 (3.037-
3.695) 
ns 
Observed Richnessc 76.71 (66.55-
85.07) 
78.80 (63.91-
96.15) 
85.57 (68.58-
104.80) 
ns 
Pielou’s Evennessc 0.706 (0.657-
0.751) 
0.677 (0.681-
0.707) 
0.696 (0.635-
0.749) 
ns 
Energy intake (kJ/day) 8672 (2054) 9939 (1710) 9662 (2323) ns 
Total carbohydrate (% of 
energy) 
41.4 (7.6) 39.8 (5.2) 45.3 (6.8) ns 
Sugars (% of energy) 14.6 (5.3) 17.2 (4.5) 19.9 (5.4) 0.0086 
Protein (% of energy) 16.4 (3.1) 15.1 (2.0) 14.8 (1.6) ns 
Total fat (% of energy) 36.7 (5.6) 39.9 (5.5) 34.6 (5.8)a 0.0418 
Saturated fat (% of energy) 12.3 (2.5)a 14.6 (3.1) 12.9 (3.1) 0.0279 
Alcohol (g/day) 9.3 (0.4-25.5) 13.1 (5.9-22.6) 12.2 (9.4-19.1) ns 
Dietary fibre (g/day) 22 (5) 23 (7) 27 (12) ns 
Sodium (mg/day) 3138 (834) 3398 (777) 2833 (713) ns 
     
aSignificantly different from OW Control group (P < 0.05). bn = 31for the T2D group. cn = 20, n = 13 and n = 12 672 
for the T2D, OW and NW group, respectively. n/a: not measured. NW group: n = 13 for dietary data. BP: blood 673 
pressure (sys: systolic, dia: diastolic).  674 
 675 
676 
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Table 3. Clinical outcomes in normal (LP) and high (HP) colonic permeability groups. Data are 677 
presented as means (SD) or median (interquartile range). 678 
 T2D patients   Controls  
 LP HP P-value  LP HP P-value 
n 19 13 -   19 11 -  
51Cr-EDTA 6-24h (%) 1.17 (0.99-
1.36) 
2.19 (1.81-
3.10) 
<0.0001  1.16 (0.90-
1.47) 
1.87 (1.64-
2.09) 
<0.0001 
Age (years) 58.2 (6.3) 57.4 (6.2) ns  56.6 (7.0) 57.5 (7.9) ns 
Weight (kg) 86.6 (12.7) 91.0 (12.9) ns  84.6 (13.6) 73.5 (10.7) 0.029 
BMI (kg/m2) 27.5 (3.3) 29.7 (3.9) ns  26.6 (4.5) 24.2 (3.0) ns 
Body fat (%) 25.0 (4.7) 27.4 (5.1) ns  22.7 (7.3)* 20.9 (4.7) ns 
Waist circumference (cm) 100.1 (10.1)* 104.9 (10.6) ns  97.6 (14.0) 89.5 (6.9) ns 
Blood pressure, systolic 
(mm Hg) 
135 (10)* 135 (12) ns  127 (10) 125 (16) ns 
Blood pressure, diastolic 
(mm Hg) 
85 (6)* 84 (8) ns  82 (9) 82 (9) ns 
HbA1c (mmol/mol) 47.4 (6.6) 51.2 (12.4) ns  n/a n/a - 
HbA1c (%) 6.5 (0.4) 6.8 (1.3) ns  n/a n/a - 
Fasting glucose (mmol/L) 5.8 (1.1) 6.7 (1.1) 0.034  4.7 (0.6) 4.6 (0.6) ns 
Fasting insulin (pmol/L) 81.4 (47.9-
111.7) 
70.0 (50.3-
132.2) 
ns  51.5 (41.9-
77.7) 
42.3 (35.6-
53.4) 
ns 
HOMA %B 112.5 (44.5) 86.2 (40.0) ns  127 (109-
147) 
111 (86-134) ns 
HOMA %S 54.1 (41.8-
87.2) 
59.9 (35.2-
85.1) 
ns  92.6 (61.1-
111.5) 
109.3 (88.3-
140.6) 
ns 
HOMA IR 1.88 (1.15-
2.40) 
1.67 (1.19-
2.97) 
ns  1.08 (0.90-
1.64) 
0.91 (0.71-
1.13) 
ns 
Total cholesterol (mmol/L) 3.5 (1.0) 3.3 (0.7) ns  5.0 (1.0) 5.4 (0.7) ns 
LDL cholesterol (mmol/L) 2.0 (0.9) 1.9 (0.6) ns  3.3 (0.8) 3.5 (0.7) ns 
HDL cholesterol (mmol/L) 1.0 (0.2) 1.0 (0.3) ns  1.2 (0.4) 1.5 (0.4) 0.040 
NEFA (mmol/L) 0.60 (0.22) 0.77 (0.26) 0.05  0.47 (0.20) 0.45 (0.28) ns 
TAGs (mmol/L) 1.06 (0.44) 0.91 (0.32) ns  0.95 (0.79-
1.13) 
0.86 (0.73-
1.03) 
ns 
hsCRP (mg/L) 1.3 (0.6-1.7) 1.5 (0.5-4.4) ns  2.7  (6.0) 1.5 (1.6) ns 
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IL-6 (pg/mL) 8.5 (7.0-12.6) 13.3 (5.5-
14.9) 
ns  7.0 (5.5-20.3) 19.6 (8.5-30.3) ns 
TNF-α (pg/mL) 13.0 (5.0-
22.3) 
8.2 (5.0-17.7) ns  7.0 (5.0-13.0) 7.0 (5.0 -13.0) ns 
LPS (EU/mL) 0.93 (0.50-
1.38) 
0.49 (0.38-
1.05)† 
ns  0.68 (0.40-
1.08) 
0.84 (0.48-
1.00) 
ns 
LBP (µg/mL) 11.0 (3.1) 10.3 (4.7) ns  10.5 (7.6-
13.3) 
10.3 (9.0-11.5) ns 
sCD14 (µg/mL) 1.03 (0.78-
1.37) 
0.94 (0.77-
1.09) 
ns  0.88 (0.82-
1.11) 
1.11 (0.82-
1.29) 
ns 
Metformin (n/%) 14/73.7 9/69.2 -  n/a n/a - 
Statins (n/%) 14/73.7 7/53.8 -  1/5.3 1/9.1 - 
BP medication (n/%) 10/52.3 8/61.5 -  2/10.5 0/0 - 
Aspirin (n/%) 3/15.8 3/23.1 -  0/0 0/0 - 
*n = 18. † n = 12. 679 
  680 
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Table 4. Dietary intakes based on 7-day diet diaries (means (SEM) or median (interquartile range)). 681 
 T2D patients   Controls  
 
LP HP 
P-
value  LP HP 
P-
value 
n 19 13   18 11  
Energy (kJ) 9187 
(1849) 
7921 
(2176) 
ns  10476 (1818) 8733 (1796) 0.018 
Dietary fibre (g/day) 23 (6) 20 (5) ns  25 (22-34) 17 (16-24)  0.022 
Alcohol (g/day) 13 (13) 12 (12) ns  15 (9) 13 (9) ns 
Sodium (mg/day) 3249 (947) 2975 (635) ns   3322 (3086-
3659) 
2530 (1903-
3580) 
ns 
Total carbohydrate (% of 
energy)  
41.7 (9.0) 40.8 (5.1) ns  43.0 (7.0) 41.1 (5.6) ns 
Sugars (% of energy) 15.4 (6.1) 13.5 (3.7) ns  19.3 (5.4) 17 (4.2) ns 
Protein (% of energy) 15.8 (3.3) 17.2 (2.5) ns  15.2 (2.2) 14.6 (1.1) ns 
Total fat (% of energy) 36.5 (6.0) 37.0 (5.3) ns  36.8 (6.3) 38.8 (5.9) ns 
Saturated fat (% of energy) 12.3 (2.2) 12.1 (2.9) ns  13.3 (2.5) 14.7 (4.1) ns 
Alcohol (% of energy) 3.8 (0-8.7) 3.1 (0.3-
6.5) 
ns  4.2 (2.8) 4.3 (3.1) ns 
 682 
 683 
 684 
  685 
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 686 
Table 5. Diversity, richness and evenness indices in T2D patients and controls. Values are means and 687 
SDs.  688 
 T2D patients   Controls  
 LP HP P-value  LP HP P-value 
n 11 9   16 9  
Richness 73.9 (17.9) 80.2 (22.2) 0.456  85.0 (19.9) 76.8 (19.8) 0.328 
Evenness 0.70 (0.09) 0.72 (0.02) 0.787  0.70 (0.10) 0.66 (0.09) 0.354 
Diversity (Shannon) 3.27 (0.48) 3.32 (0.38) 0.941  3.34 (0.56) 3.12 (0.54) 0.598 
Diversity (Simpson) 0.91 (0.05) 0.91 (0.04) 0.520  0.89 (0.10)  0.87 (0.11) 0.337 
Diversity (Fisher’s) 24.6 (6.7) 27.1 (10.2) 0.498  30.2 (9.7) 26.3 (9.4) 0.403 
 689 
  690 
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Table 6. RDP and NCBI taxonomy and annotation. When more than one match (99-100%) was found, 691 
three accession numbers are listed. 692 
 693 
OTU RDP taxonomy NCBI taxonomy Query 
cover/identity 
NCBI 
accession no. 
OTU_3 Unclassified 
Bacteriodes Bacteroides vulgatus ATCC 8482 
100/99 NC_009614 
 
OTU_5 Unclassified 
Enterobacteriaceae 
Escherichia coli O83:H1 str. NRG 857C, 
Escherichia coli str. K-12 substr. MG1655, 
Escherichia coli UMN026 chromosome 
100/99 NC_017634 
NC_000913.3 
NC_011751 
OTU_7 Unclassified 
Bacteroidetes 
No 99-100% match.    
OTU_14 Prevotella No 99-100% match.   
OTU_20 Unclassified 
Ruminococceae  
No 99-100% match.   
OTU_44 Clostridium XIVa No 99-100% match.   
OTU_50 Blautia No 99-100% match.   
OTU_72 Unclassified_Rumi
nococcaceae 
No 99-100% match.   
OTU_93 Unclassified_Lachn
ospiraceae 
No 99-100% match.   
OTU_109 Faecalibacterium  No 99-100% match.   
OTU_129 Parasuttarella Parasutterella excrementihominis YIT 11859 
genomic scaffold Scfld40 
100/100 NZ_GL883702 
 
OTU_131 Unclassified 
Lachnospiraceae 
No 99-100% match.   
OTU_151 Unclassified 
Lachnospiraceae 
No 99-100% match.   
OTU_177 Sutterella Sutterella wadsworthensis 2_1_59BFAA 100/99 NZ_JH815522, 
NZ_JH815517, 
NZ_JH815517  
OTU_180 Ruminococcus Ruminococcus callidus ATCC 27760 100/100 NZ_KI260393 
OTU_195 Clostridium XI Clostridium sp. 01 genomic scaffold, 
scaffold00220 
99/99 NZ_HG529443 
 
OTU_329 Unclassified 
Firmicutes 
No 99-100% match.    
  694 
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Figure 1. Unweighted (a) and weighted (b) UniFrac distances in T2D patients and normal weight (NW) 695 
and overweight/obese (OW) controls. There were significant differences between groups in the class 696 
Enterobacteriales, genus unclassified Enterobacteriaceae and Escherichia coli (OTU 5) between 697 
normal weight (NW) controls (n=12), overweight/obese (OW) controls (n=13) and T2D patients (n=20) 698 
(c-e). FDR adjusted P-values are displayed in the header of the panels.  699 
Figure 2. Total bacteria and selected bacterial groups were quantified by real time qPCR (median, 700 
interquartile ranges and min and max values, n=23, n=15 and n=12 for T2D, OW and NW control 701 
groups, respectively). Although post-hoc tests showed that total bacteria were significantly higher in 702 
control NW compared to control OW (P = 0.030), there was only a trend towards a main effect (P = 703 
0.0516) (a). Abundances of Lactobacillus spp. and C. leptum and C. coccoides clusters were 704 
significantly different between groups (P = 0.0062, P < 0.0001 and P<0.0001, respectively) with 705 
significantly higher levels in T2D compared to control OW (P = 0.0183, P < 0.0001 and P = 0.004, 706 
respectively) (c, f and g). Whilst Roseburia spp. and Bifidobacterium spp. did not differ between groups 707 
(P = 0.9835 and P = 0.1660) (b and d), there was a trend towards a differences in Enterobacteriaceae 708 
between groups (P = 0.0504) (e). 709 
Figure 3. Correlation heat maps showing associations (Kendall’s rank correlations) between clinical 710 
outcomes (adjusted for multiple testing). Due to missing data for some participants, correlations 711 
coefficients were not calculated for waist circumference and LPS. Normal weight (NW) controls: n=12, 712 
overweight/obese (OW) controls: n=13, and T2D patients: n=20. 713 
Figure 4. Differences in abundances of several bacteria in type 2 diabetes patients (a and b) and controls 714 
(c and d) colonic HP and LP groups were found. Taxonomic annotation and adjusted P-values are 715 
displayed in the headers. T2D HP: n = 9, T2D LP: n = 11, Control HP: n = 9, Control LP: n = 16. 716 
Figure 5. (a) Bray-Curtis distances in control groups (OW: overweight/obese (n = 13), NW: normal 717 
weight (n = 12) and metformin-treated type 2 diabetes patients (Diabetic – Yes, n =13) and diabetes 718 
patients not treated with metformin (Diabetic – No, n = 7)). The circles show the 95% confidence 719 
intervals and the subgroup legends in the plot represent the mean value of each group. Significant 720 
differences in bacterial abundances between groups were found at the order (b), family (c), genus (d) 721 
and (e) levels.   722 
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